Mindset Pharma
Pioneering next-generation psychedelic medicines for neurological and psychiatric disorders. Learn more
Launch date
Employees
Market cap
$56.5m
Enterprise valuation
$51m (Public information from Oct 2023)
Share price
€0.493 9DF.F
Toronto Ontario (HQ)
Financials
Estimates*
| CAD | 2018 | 2019 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 3.9m | - | - | 3.9m |
| EBITDA | (<1m) | (<1m) | (5.3m) | (16.5m) |
| % EBITDA margin | - | - | - | (423 %) |
| Profit | (<1m) | (<1m) | (11.7m) | (16.6m) |
| % profit margin | - | - | - | (425 %) |
| R&D budget | 7.4m | 7.4m | 2.2m | 7.4m |
| R&D % of revenue | 189 % | - | - | 189 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
* | CAD80.0m Valuation: CAD80.0m 20.5x EV/LTM Revenues -4.8x EV/LTM EBITDA | Acquisition | |
| Total Funding | - | ||
Related Content
Recent News about Mindset Pharma
EditMore about Mindset Pharmainfo icon
EditMindset Pharma is a drug discovery business, based in Toronto, Canada, focused on creating novel and patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. The Company is traded under the ticker symbol MSET on the CSE
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.